Abstract: Bone growth during childhood and puberty determines an adult’s final stature. Although several prior studies have reported that fermented oyster (FO) consisting of a high amount of gamma aminobutyric acid can be attributed to bone health, there is no research on the efficacy of FO on growth regulation and the proximal tibial growth plate. Therefore, in this study, we investigated the effect of FO oral administration on hepatic and serum growth regulator levels and the development of the proximal tibial growth plate in young Sprague-Dawley rats. Both oral administration of FO (FO 100, 100 mg/kg FO and FO 200, 200 mg/kg FO) and subcutaneous injection of recombinant human growth hormone (rhGH, 200 µg/kg of rhGH) for two weeks showed no toxicity. Circulating levels of growth hormone (GH) significantly increased in the FO 200 group. The expression and secretion of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) were enhanced by FO administration. FO administration promoted the expression of bone morphogenic proteins IGF-1 and IGFBP-3 in the proximal tibial growth plate. This positive effect of FO resulted in incremental growth of the entire plate length by expanding the proliferating and hypertrophic zones in the proximal tibial growth plate. Collectively, our results suggested that oral administration of FO is beneficial for bone health, which may ultimately result in increased height.

Keywords: fermented oyster; gamma aminobutyric acid; insulin like growth factor-1; recombinant human growth hormone; tibial growth plate
In addition, it is well known that oyster meat is a high-quality marine food resource that contains several vitamins and minerals [2]. Numerous studies have reported that oysters and their bioactive peptides have pharmacological benefits including anti-oxidant [3], anti-microbial [4], osteogenic [5,6], anti-inflammatory [7], postprandial blood glucose control [8], and anti-coagulant properties [1].

Fermentation is a natural or controlled food preservation technique that extends shelf-life and improves flavor and nutrition [9]. Several reports have estimated that the biochemical components of oysters changed during fermentation, altering its biological activities [10–12]. Je et al. [10] suggested that during oyster sauce fermentation, the major free amino acids increased including taurine, glutamic acid, glycine, leucine, alanine, and lysine. They also reported that peptides isolated from fermented oyster (FO) sauces possessed angiotensin-converting enzyme inhibitory activity, and oral administration of these peptides suppressed blood pressure in spontaneously hypertensive rats [11]. Recently accumulated evidence has established that FO is attributed to bone health [12–15]. Data published in 2019 demonstrated that FO prevented ovariectomy-induced bone loss and suppressed osteoclastogenesis [13]. A recent study reported that FO promotes bone formation by osteoblast differentiation via activating the Wnt/β-catenin signaling pathway in mouse pre-osteoblast MC3T3-E1 cells, human osteoblast-like MG-63 cells, and zebrafish larvae [14]. Our previous study suggested that FO attenuates osteoclastogenesis via suppression of reactive oxygen species in mouse macrophage cells [15]. We recently demonstrated that fermentation of oyster by Lactobacillus brevis BJ20 increased the amount of gamma aminobutyric acid (GABA), which may contribute to increased height in Sprague-Dawley (SD) rats [12]. GABA is associated with bone health and might be a biomarker of osteoporosis diagnosis and therapy [16]. According to a recent report, high levels of serum GABA were observed in young women, which plays a positive role in physical activity, whereas GABA levels were lower in elderly women with osteoporotic fractures [16]. Our previous study suggested that FO has rich GABA content and increases body length and hepatic insulin-like growth factor-1 (IGF-1) synthesis [12]. However, there are limitations that no statistical significance on circulating growth hormone levels and bone morphometric parameters upon oral administration of 100 mg/kg FO. Therefore, the present study assessed the efficacy of high doses of FO in growing rats. We observed the efficacy on growth upon oral administration of 200 mg/kg FO for two weeks in young SD rats. We also investigated the effect of oral FO administration on hepatic and serum growth regulator levels and the development of the proximal tibial growth plate.

2. Results

2.1. Fermented Oyster (FO) Administration Has No Toxicity

The body weight gains of the FO100 (64.97 ± 5.78 g), FO200 (63.92 ± 1.87 g), and rhGH (70.04 ± 8.70 g) groups were similar to those of the normal group (62.43 ± 8.95 g). Body weight gain was not significantly different between all groups, although body weight gain was slightly increased in the treated groups (data not shown). Meanwhile, the changes in hematological profiles following FO administration were investigated. Red blood cells (RBC), white blood cells (WBC), hematocrit, hemoglobin, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), MCH concentration (MCHC), and platelets showed no differences among all of the groups (Table 1). There was no difference between each group in the values of the biochemical indices including alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine, and calcium (Table 1).

2.2. FO Increased the Expression of Hepatic Insulin-Like Growth Factor-1 (IGF-1) and Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3)

We evaluated the effect of FO administration on the expression of IGF-1 and IGFBP-3 in liver tissue. Analysis of the effects of test substances on hepatic IGF-1 expression showed that the expression significantly increased to 3.86-fold of normal in the FO200 group (Figure 1A,B). The expression of hepatic IGFBP-3 was also markedly increased by FO200 administration (4.49-fold of normal, Figure 1C,D).
Administration of FO100 did not affect the expression of IGF-1 and IGFBP-3 in the liver tissue. However, the expression of hepatic IGF-1 and IGFBP-3 were remarkably upregulated by recombinant human growth hormone (rhGH) injection (IGF-1, 4.72-fold of normal; IGFBP-3, 4.15-fold of normal).

Table 1. Hematological and biochemical analysis of the Sprague-Dawley rats 14 days after treatment.

| Parameter (Units) | Normal | FO100 | FO200 | rhGH |
|-------------------|--------|-------|-------|------|
| RBC (106/μL)      | 6.83 ± 0.42 | 6.77 ± 0.40 | 6.81 ± 0.37 | 6.84 ± 0.33 |
| WBC (103/μL)      | 3.44 ± 0.38 | 3.52 ± 0.59 | 3.68 ± 0.64 | 3.15 ± 0.76 |
| Hematocrit (%)    | 50.11 ± 2.32 | 49.74 ± 2.08 | 51.00 ± 1.93 | 49.93 ± 2.15 |
| Hemoglobin (g/dL) | 14.55 ± 0.74 | 14.36 ± 0.49 | 14.64 ± 0.63 | 14.37 ± 0.58 |
| MCV (fL)          | 72.68 ± 1.83 | 72.33 ± 1.54 | 73.41 ± 1.92 | 73.51 ± 1.75 |
| MCH (pg)          | 21.42 ± 0.53 | 21.04 ± 0.44 | 20.79 ± 0.67 | 21.28 ± 0.53 |
| MCHC (g/dL)       | 28.97 ± 0.36 | 28.35 ± 0.42 | 27.85 ± 0.39 | 28.72 ± 0.35 |
| Platelet (103/μL) | 1217.49 ± 236.81 | 1334.52 ± 201.57 | 1294.63 ± 194.68 | 1315.44 ± 186.37 |
| ALT (U/L)         | 13.72 ± 1.02 | 13.44 ± 0.85 | 12.96 ± 0.78 | 13.35 ± 0.89 |
| AST (U/L)         | 24.38 ± 2.72 | 21.06 ± 2.47 | 22.41 ± 3.11 | 20.85 ± 3.26 |
| BUN (mg/dL)       | 19.15 ± 2.34 | 20.27 ± 2.75 | 18.89 ± 3.06 | 18.12 ± 2.51 |
| Creatinine (mg/dL)| 0.29 ± 0.04 | 0.29 ± 0.04 | 0.29 ± 0.02 | 0.28 ± 0.04 |
| Calcium (mg/dL)   | 12.84 ± 0.65 | 12.37 ± 0.39 | 12.27 ± 0.41 | 12.33 ± 0.43 |

Results are expressed as means ± SD of eight rats in each group. 1 Normal distilled water was orally administered; FO100, 100 mg/kg/day of fermented oyster (FO) extract was orally administered; FO200, 200 mg/kg/day of FO was orally administered; rhGH, 200 µg/kg/day of recombinant human growth hormone (rhGH) was subcutaneously injected. 2 RBC, red blood cells; WBC, white blood cells; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, MCH concentration; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen.

Figure 1. The protein expression of hepatic IGF-1 and IGFBP-3. Liver extract from Sprague-Dawley rats 14 days after treatment were analyzed via western blotting with anti-IGF-1 (A) and anti-IGFBP-3 (C) antibodies. β-actin served as the loading control. (B,D) Quantification of IGF-1 and IGFBP-3 levels. Data are expressed as means ± SD (n = 6). * p < 0.05, ** p < 0.01 and, *** p < 0.001 vs. normal. IGF-1, insulin-like growth factor-1; IGFBP-3, insulin-like growth factor binding protein-3.
2.3. FO Induced Circulating Levels of Growth Hormone (GH), IGF-1, and IGFBP-3

Changes in the serum GH, IGF-1, and IGFBP-3 levels following FO administration were then estimated. As shown in Figure 2A, FO200 administration increased the serum GH levels, which had statistical significance (2.85-fold of normal, *p* < 0.05), and the levels were also elevated by rhGH injection (5.42-fold of normal). The circulating levels of IGF-1 noticeably increased in the FO100 and FO200 administration groups, and the levels were similar to the rhGH group (Figure 2B). The serum IGFBP-3 levels were markedly upregulated by FO200 administration (1.28-fold of normal) and rhGH injection (1.36-fold of normal), but not FO100 (Figure 2C).

![Figure 2](image_url)

**Figure 2.** The serum GH (A), IGF-1 (B), and IGFBP-3 (C) levels. Serum from Sprague-Dawley rats 14 days after treatment were analyzed using commercial ELISA kits. Data are expressed as means ± standard deviation (SD, *n* = 6). *p* < 0.05 and **p* < 0.01 vs. normal. GH, growth hormone; IGF-1, insulin-like growth factor-1; IGFBP-3, insulin-like growth factor binding protein-3.

2.4. FO Increased the Height of the Proximal Tibial Growth Plate

Examination of hematoxylin and eosin (H&E) stained sections of the proximal tibia revealed changes in the growth plate (Figure 3A). Treatment with rhGH (383.79 ± 45.92 μm), FO100 (385.30 ± 40.34 μm), and FO200 (410.41 ± 33.43 μm) significantly increased the growth plate’s total height compared to the vehicle treated normal group (334.69 ± 28.53 μm) (Figure 3B). Detailed measurement of the growth plate demonstrated a significant increase in the height of the proliferation zone in the treated groups compared to the normal group: normal group (138.76 ± 20.72 μm), rhGH (181.19 ± 25.38 μm), FO100 (173.48 ± 17.26 μm), and FO200 (181.54 ± 22.39 μm). As shown in Figure 3C, the height of the hypertrophic zone did not reveal significant differences between the normal (161.12 ± 19.85 μm), rhGH (153.66 ± 30.28 μm), and FO100 (162.58 ± 19.21 μm) treated groups. However, the height of the hypertrophic zone significantly increased in the FO200 (187.52 ± 21.91 μm) treated groups compared to the other groups.

2.5. FO Enhanced the Expression of Bone Morphogenetic Proteins in the Proximal Tibial Growth Plate

We next observed the changes in the expression of bone morphogenic proteins in the tibial growth plate following FO administration. Bone morphogenetic protein (BMP)-2 expression was higher in the hypertrophic zones than in the proliferative zones in the proximal tibial growth plate (Figure 4A,B). The expression of BMP-2 was markedly increased by FO200 administration and rhGH injection. As shown in Figure 4C,D, in the normal group, BMP-4 was more highly expressed in the proliferative zone than in the hypertrophic zone. The expression of BMP-4 in the proliferative zone was not different between the groups. However, the expression of BMP-4 in the hypertrophic zone was markedly enhanced by FO administration in a dose-dependent manner. The rhGH injection induced marked incremental expression of BMP-4 in the hypertrophic zone in the proximal tibial growth plate.
The expression of IGFBP-3 in the hypertrophic zone was markedly enhanced by FO administration and rhGH injection. In addition, rhGH injection enhanced IGF-1 expression, which was similar to the result in the FO200 group. The administration of FO substantially increased IGF-1 expression, with a concentration-dependent tendency. The rhGH injection increased IGF-1 expression in a dose-dependent manner. The rhGH injection significantly increased IGF-1 expression in both the proliferative and hypertrophic zones, and its increase had a concentration-dependent tendency.

Figure 3. Histology of the proximal tibial growth plate in the Sprague-Dawley rats and height measurements. (A) Hematoxylin & eosin (H&E) staining of the proximal tibial growth plate (100× magnification). (B) Heights of the entire growth plate were measured on tibial sections stained with H&E. (C) Length of the proliferating zone in the growth plates. (D) Length of the hypertrophic zone in the growth plates. Heights were measured on tibial sections stained with H&E (100×). Data are expressed as means ± SD (n = 6). * p < 0.05 and ** p < 0.01 vs. normal. PZ, proliferating zone; HZ, hypertrophic zone.

Figure 4. Immunohistochemical localization of bone morphogenic proteins in the proximal tibial growth plate. BMP-2 (A) and BMP-4 (C) were detected in the proliferating and hypertrophic zone of the proximal tibial growth plate. Scale bar; 50 μm. (B,D) The stained area of BMP-2 and BMP-4 was analyzed using ImageJ® and calculated in terms of the fold of the control. Data are expressed as means ± SD (n = 6). ** p < 0.01 and *** p < 0.001 vs. normal. BMP-2, bone morphogenetic protein-2; BMP-4, bone morphogenetic protein-4; PZ, proliferating zone; HZ, hypertrophic zone.
2.6. FO Promoted the Expression of IGF-1 and IGFBP in the Proximal Tibial Growth Plate

To investigate whether FO administration regulated the expression of IGF-1 and IGFBP-3 in the proximal tibial growth plate, we performed additional immunohistochemical analysis. Our results showed that IGF-1 was only slightly expressed in both the proliferative and hypertrophic zones (Figure 5A,B). However, the administration of FO substantially increased IGF-1 expression in both the proliferative and hypertrophic zones, and its increase had a concentration-dependent tendency. In addition, rhGH injection enhanced IGF-1 expression, which was similar to the result in the FO200 group. In the proliferative zone, there was no difference in the expression of IGFBP-3 between the groups (Figure 5B–D). However, the expression of IGFBP-3 in the hypertrophic zone was markedly enhanced by FO administration and rhGH injection.

![Figure 5](image.png)

**Figure 5.** Immunohistochemical localization of IGF-1 and IGFBP-3 in the proximal tibial growth plate. IGF-1 (A) and IGFBP-3 (C) were detected in the proliferating and hypertrophic zones in the proximal tibial growth plate. Scale bar, 50 µm. (B, D) The stained area of IGF-1 and IGFBP-3 was analyzed using ImageJ® and calculated in terms of the fold of the control. Data are expressed as means ± SD (n = 6). * p < 0.05 and *** p < 0.001 vs. normal. IGF-1, insulin-like growth factor-1; IGFBP-3, insulin-like growth factor binding protein-3; PZ, proliferating zone; HZ, hypertrophic zone.

3. Discussion

GABA is a non-protein amino acid that is widely distributed in microorganisms, plants, and animals, and is produced by glutamate decarboxylase that catalyzes the irreversible decarboxylation of L-glutamate to GABA [17,18]. A number of microorganisms of bacteria and fungi have been reported to produce GABA [19]. Among the microorganisms, lactic acid bacteria is the most practical group of bacteria for GABA production, which makes high levels of GABA [19]. Recently, *Lactobacillus brevis* and *Lactococcus lactis* isolated from many fermented foods have been used for the mass production of GABA [20]. A wide range of traditional foods produced by microbial fermentation contain GABA, in which GABA is safe and eco-friendly, and also has the possibility of providing new health-benefited products enriched with GABA [21]. Numerous studies have demonstrated that GABA-enriched functional food have physiological benefits such as suppression of blood pressure [22], hepatoprotection [23], decrease in gut inflammation [24], and regulation of glucose tolerance [25]. Furthermore, several reports have demonstrated that GABA promoted bone health [15,16,26–28].
Watanabe et al. [26] reported that GABA directly regulates the muscle tone, and Muhammad et al. [27] suggested GABA promotes osteoblastogenesis by stimulation of bone formation genes. More recently, Jeong et al. [15] found that GABA-enriched seaweed suppressed osteoclastogenesis. Additionally, one study reported that peripheral GABA increases plasma GH concentration in humans [28]. In this regard, our previous finding demonstrated that FO had a high content of GABA by fermentation with \textit{Lactobacillus brevis} BJ20 [12]. Our recent reports suggest that FO prevented osteoclast differentiation, stimulated bone formation, and proposed the possibility of promotion on bone growth [12–14]. Based on these previous studies, we considered that the beneficial effect of FO on bone health was associated with a high content of GABA. Therefore, in the present study, we investigated the effect of GABA-enriched FO on hepatic and serum growth regulator levels and the development of the proximal tibial growth plate in SD rats.

The development of the human body is a multifactorial process involving bone tissue accumulation influenced by genetic, nutritional, environmental, and hormonal factors [29]. This process begins during the fetal age and ends in adolescence with the fusion of the epiphyseal growth plate, which determines an individual’s final stature. [30]. Therefore, childhood and pubertal growth has an important impact on height and depends on GH, which has long been established as a longitudinal growth regulator [31,32]. GH is the main hormone involved in growth and has a stimulatory effect on osteoblast precursors and stimulate osteoblast proliferation and activity [32,33]. In the liver, GH accelerates IGF-1 synthesis and subsequently secretion in the blood [33]. GH stimulates the local production of IGF-1 through a direct effect on cartilage cells in the growth plates [34]. IGF-1 is primarily present in a complex form with IGFBP-3, which is synthesized in the liver, and it plays a significant role in growth-plate mediated growth [35,36]. In this respect, numerous reports have established that longitudinal bone growth is stimulated by IGF-1, which has been proposed to play an essential role in bone metabolism [37,38]. Moreover, IGFBP-3 is considered as a biochemically excellent index of GH level due to it is GH dependent and is maintained at a regular daily concentration [39]. Actually, several studies have suggested that the level of IGFBP-3 may be superior to the measurement of IGF-1 in the diagnosis of GH deficiency, and in reflecting actual serum levels of IGF-1 [40–42]. In 2016, Lee et al. also demonstrated that oral administration of \textit{Phlomis umbrosa} root increased longitudinal bone growth rate by stimulating proliferation and hypertrophy of chondrocyte with the increment of circulating IGFBP-3 [43]. Furthermore, Kim et al. reported that oral administration of herbal extracts increased the expression of IGF-1 and IGFBP-3 on the growth plate, and most rats had a direct proportional relationship between IGF-1 and IGFBP-3 [44]. Therefore, observations of changes in circulating GH, IGF-1, and IGFBP-3 as well as hepatic IGF-1 and IGFBP-3 expression are important for growth evaluation. In the present study, we evaluated the effect of high doses of FO on growth regulators including GH, IGF, and IGFBP-3 in young SD rats. In accordance with previous studies, our findings showed that the administration of FO 200 mg/kg stimulated the levels of serum GH as well as the expression of IGF-1 in liver and blood (Figures 1 and 2). We found it interesting that in the FO 200 mg/kg group and rhGH group, the IGFBP-3 levels were increased in the liver and blood. In addition, the local expression of IGF-1 and IGFBP-3 was also observed in the hypertrophic zone in the proximal tibial growth plate (Figure 5). These results suggested that oral administration of FO positively regulates circulating and hepatic IGF-1 and IGFBP-3 via incremental GH secretion and has a direct impact on the local proximal tibial growth plate, ultimately contributing to growth.

During childhood, bone mass accretion is a combination of bone remodeling and bone growth [33]. Bone remodeling is the course of new bone formation and resorption by osteoblasts and osteoclasts, respectively [33]. GH regulates both osteoblast proliferation and promotes bone formation, and osteoclast differentiation stimulates bone resorption [45]. Accumulated evidence supports that FO regulates bone remodeling and has a net effect on bone accretion by suppressing osteoclastogenesis and promoting osteogenesis [13,14]. Bone growth primarily occurs at the growth plates and depends on the proliferation and differentiation of chondrocytes [46,47]. The growth plate consists of three principal zones: the resting, proliferative, and hypertrophic zones [48]. The resting zone is adjacent to
the epiphyseal bone and maintains the growth plate [49]. The proliferative zone contains replicating chondrocytes arranged in columns parallel to the bone’s long axis [46–48]. Terminally differentiated chondrocytes enlarge to become hypertrophic chondrocytes that maintain a columnar alignment in the hypertrophic zone [46–48]. In the present study, we investigated the effect of FO on histological changes in the proximal tibial growth plate. Our results showed that FO administration markedly increased the expansion of the proliferative and hypertrophic zones in the growth plate (Figure 3). FO also contributes to increasing the entire growth plate length. Numerous studies suggested that bone growth results in the expansion of the proliferative and hypertrophic zones in growth plates with associated matrix synthesis [48,50]. The oral administration of FO promotes the enlargement of the proximal tibial growth plate, increasing height.

Bone morphogenetic proteins (BMPs) are multifunctional growth factors that play a critical role in bone formation [51]. BMP signal activation is required for undifferentiated mesenchymal cells to become precursors of osteoblasts and chondrocytes [51,52]. Shu et al. reported knockdown of BMP-2 and BMP-4 due to disorganization of chondrocytes, dysregulation of differentiation, and increased apoptosis in the growth plate [53]. Another study showed that BMP-2-deficient mice demonstrated failed fracture healing due to the absence of chondrogenesis at injured lesions [54]. Another study also demonstrated that BMP is required for normal osteogenesis and is a key regulator promoting proper endochondral bone formation [55]. In line with these findings, our results showed that FO promoted the expression of BMP-2 and BMP-4 in the hypertrophic zone in the proximal tibial growth plate. Based on this result, oral administration of FO upregulates BMP expression in the growth plate and may contribute to bone health via bone formation.

In summary, administration of GABA-enriched FO has no toxicity and markedly increased the hepatic expression and circulating levels of GH, IGF-1, and IGFBP-3. Administration of FO substantially upregulated the expression of BMPs, IGF-1, and IGFBP-3 in the hypertrophic zone of the proximal tibial growth plate. These effects of FO contribute to increasing the length of the entire growth plate in the proximal tibia, which may ultimately result in increased height (Figure 6).

![Figure 6](image_url)  
Figure 6. GABA-enriched FO promoted the length of the growth plate on the longitudinal bone in the Sprague-Dawley rats.

4. Materials and Methods

4.1. Preparation of Fermented Oyster

FO extract was obtained from Marine Bioprocess Co. Ltd. (Busan, Korea). In brief, the FO used in this study was oyster fermented with *L. brevis* BJ20, and glutamic acid and dextrin were used on behalf of glutamate and an excipient, respectively. Glutamate was used as a precursor to produce GABA through a decarboxylation reaction during fermentation with *L. brevis* BJ20 [56]. In the present study,
used FO was the same batch as used that in a previous report [12], which was comprised of 46 g/100 g carbohydrate, 36 g/100 g crude protein, 6.3 g/100 g sugars, and 114 mg/g GABA. FO was diluted with distilled water immediately before use.

4.2. Animal Study

Female Sprague-Dawley rats (three weeks old) were purchased from Koatech Laboratory Animals, Inc. (Pyeongtaek, Gyeonggi, Korea) and adapted for one week. All of the procedures were followed in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Dong-eui University (No. R2019–002). Thirty-two rats were randomly assigned to four groups of eight rats: group 1 (normal, 100 µL of distilled water), group 2 (100 µL of 100 mg/kg FO), group 3 (100 µL of 200 mg/kg FO), and group 4 (subcutaneous injection of 200 µg/kg rhGH; Growtropin-II Dong-A ST Co. Ltd., Seoul, Korea). Groups 1, 2 and 3 were orally administrated directly into the stomach of rats via metal gavage needles (Braintree Scientific, Braintree, IL, MA), while Group 4 was subcutaneously injected. All of the treatments were administered once a day in the morning for two weeks. The body weight was measured weekly. All of the rats were given ad libitum access to standard chow and water and sacrificed on day 14 of the study.

4.3. Collection of Blood and Tissue Samples

Blood samples were collected from the heart using BD Vacutainer ethylenediaminetetraacetic acid (EDTA)-containing tubes (Becton Dickinson, Franklin Lakes, NJ, USA). Whole blood samples were used for hematological analysis. Serum samples that were obtained by centrifugation at 3000 g for 10 min were stored at −80 °C for later biochemical and ELISA analyses. After perfusion, liver samples were immediately surgically excised and stored at −80 °C for western blotting. Longitudinal bone was dissected, fixed 10% formalin overnight, and decalcified for one month in 0.5 M EDTA (pH 7.4) at 4 °C with constant shaking. Tissues were dehydrated by passage through an ethanol series, cleared three times in xylene, embedded in paraffin, and sectioned to 5 µm with a microtome (Leica Biosystems, Nussloch, Germany). Paraffin sections of the proximal tibia then underwent histochemical and immunohistochemical analysis.

4.4. Hematological and Biochemical Analysis

The hematological analyses were conducted using a Sysmex XN-9000 analyzer (Sysmex Corporation, Kobe, Japan) to assess the complete blood count: RBC, WBC, hematocrit, hemoglobin, MCV, MCH, MCHC, and platelet counts. The biochemical analysis was validated using a Cobas 8000 C702 chemistry analyzer (Roche, Mannheim, Germany). Components including ALT, AST, BUN, creatinine, and calcium were detected as previously described [57].

4.5. Western Blotting Analysis

Western blotting analysis was conducted as previously described [12]. In brief, the liver tissues were lysed in radioimmunoprecipitation assay lysis buffer, and the total protein concentration was determined using Bradford Protein Assay Kits (Bio-Rad Laboratories, Hercules, CA, USA). A total of 50 µg of protein was separated on 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred to polyvinylidene fluoride (PVDF) membranes after electrophoresis. The membranes were then blocked with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Triton X-100 (TBST) for 1 h and probed for overnight at 4 °C using primary antibodies: IGF-1 (1:500, sc-74116, Santa Cruz Biotechnology, Santa Cruz, CA, USA), IGFBP-3 (1:500, sc-374365, Santa Cruz Biotechnology), and β-actin (1:2000, sc-47778, Santa Cruz Biotechnology). The PVDF membrane was washed with Tris-buffered saline (TBS) and incubated with appropriate secondary antibody (sc-2005, Santa Cruz Biotechnology) for 1 h at room temperature, then exposed with an enhanced chemiluminescence kit (GE Healthcare Life Sciences Ltd., Amersham Place, Little Chalfont, UK) at the Core-Facility Center for Tissue Regeneration, Dong-eui University (Busan, Korea). Immunoreactive proteins were scanned
with a Fusion FX Image system (Vilber Lourmat, Torcy, France). The band density was normalized according to the expression of β-actin as a loading control.

4.6. Enzyme-Linked Immunosorbent Assay

Serum GH, IGF-1, and IGFBP-3 levels were measured using an enzyme-linked immunosorbent assay (ELISA), in accordance with the manufacturer’s instructions. A rat GH solid-phase sandwich ELISA kit (KRC5311) was purchased from Thermo Fisher Scientific (Waltham, MA, USA). Quantitative sandwich ELISA kits for mouse IGF (OKBB00165) and mouse IGFBP-3 (OKBB00172) were obtained from AVIVA Systems Biology (San Diego, CA, USA).

4.7. Histochemical Analysis

Histochemical analysis of the longitudinal bone was performed using a previously described protocol with slight modifications [15,58]. Paraffin sections of the proximal tibia were dewaxed, rehydrated, and stained with hematoxylin and eosin (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) and representative images were captured using a Leica DM 2500 (Leica Biosystems, Nussloch, Germany). Regions along the center of the growth plates and proliferative and hypertrophic zones were selected for measurements. The height measurements were obtained by using iSolution software (Daejeon, Korea) at 100× magnification. At least 10 measurements were obtained for each section.

4.8. Immunohistochemistry

Immunohistochemistry of the longitudinal bone was performed as previously described [59]. Paraffin sections of the proximal tibia were dewaxed, rehydrated, cooked in antigen retrieval buffer (Abcam Inc., Cambridge, UK) for 10 min, and then incubated using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) for 30 min. The tissue sections were blocked in 5% bovine serum albumin for 1 h and then probed overnight at 4 °C with primary antibodies: BMP-2 (1:200, ab14933, Abcam), BMP-4 (1:200, ab39973, Abcam), IGF-1 (1:200, sc-74116, Santa Cruz Biotechnology), and IGFBP-3 (1:200, sc-374365, Santa Cruz Biotechnology). The sections were then applied with appropriate secondary antibodies for 1 h at room temperature and incubated in ABC reagent for 1 h. Immunoreactions were visualized with 3,3′-diaminobenzidine (DAB) peroxidase substrate and counterstained with Mayer’s hematoxylin (Sigma-Aldrich Chemical Co.). Images of the sections were photographed with a Leica DM 2500. The quantitative analysis of histological staining for BMP-2, BMP-4, IGF-1, and IGFBP-3 was performed using the “threshold tool” of ImageJ® [60].

4.9. Statistical Analysis

The results were presented as means ± standard deviation (SD). All of the data were analyzed via one-way ANOVA with Tukey’s post-hoc test (GraphPad Prism 5.03, GraphPad Software, Inc., La Jolla, CA, USA), and p < 0.05 was considered statistically significant.

5. Conclusions

Collectively, our results suggest that oral administration of FO can lengthen the proximal tibial growth plate and increase growth hormone and growth regulator in the liver and blood. FO’s effect on proximal tibial growth may be due to GABA. Although our findings demonstrated the enhancing effect of FO on the development of young rats, further studies are necessary to confirm the effect of FO on bone micro-architecture and identify the mechanism of action. More evidence is needed to demonstrate the potential benefits on childhood bone growth using clinical trials.

Author Contributions: Conceptualization, G.-Y.K., E.K.P., B.-J.L., Y.-J.J. and Y.H.C.; Methodology, S.H.H., J.-H.P.; Validation, J.-H.P. and Y.-J.J.; Investigation, H.L., H.H., S.Y.J., M.Y.K., S.Y.K. and D.H.K.; Formal analysis, H.H., S.Y.J., S.J.L., F.A.; Data curation, S.H.H., B.-J.L. and E.K.P.; Visualization, H.L. and E.K.P.; Writing—original draft preparation, H.L., G.-Y.K. and Y.H.C.; Writing—review and editing, H.L., G.-Y.K. and Y.H.C.; Supervision, Y.H.C.; Funding acquisition, G.-Y.K. All authors have read and agreed to the published version of the manuscript.
Funding: This research was part of the project titled ‘Development of functional food products with natural materials derived from marine resources (20170285)’ funded by the Ministry of Oceans and Fisheries, Republic of Korea.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Cheng, S.; Tu, M.; Liu, H.; An, Y.; Du, M.; Zhu, B. A novel heptapeptide derived from Crassostrea gigas shows anticoagulant activity by targeting for thrombin active domain. Food Chem. 2020, 334, 127507. [CrossRef]
2. Bang, J.S.; Choung, S.Y. Inhibitory effect of oyster hydrolysate on wrinkle formation against UVB irradiation in human dermal fibroblast via MAPK/AP-1 and TGFβ/Smad pathway. J. Photochem. Photobiol. B 2020, 209, 111946. [CrossRef]
3. Moon, P.D.; Kim, M.H.; Lim, H.S.; Oh, H.A.; Nam, S.Y.; Han, N.R.; Kim, M.J.; Jeong, H.J.; Kim, H.M. Taurine, a major amino acid of oyster, enhances linear bone growth in a mouse model of protein malnutrition. Biofactors 2015, 41, 190–197. [CrossRef] [PubMed]
4. Lv, X.; Wang, W.; Han, S.; Liu, S.; Yang, W.; Li, M.; Wang, L.; Song, L. The dicer from oyster Crassostrea gigas functions as an intracellular recognition molecule and effector in anti-viral immunity. Fish. Shellfish Immunol. 2019, 95, 584–594. [CrossRef] [PubMed]
5. Han, S.Y.; Lee, J.R.; Kwon, Y.K.; Jo, M.J.; Park, S.J.; Kim, S.C.; Lee, H.S.; Ku, S.K. Ostreae testa prevent ovariectomy-induced bone loss in mice by osteoblast activations. J. Ethnopharmacol. 2007, 114, 400–405. [CrossRef] [PubMed]
6. Oliveira, D.V.; Silva, T.S.; Cordeiro, O.D.; Cavaco, S.I.; Simes, D.C. Identification of proteins with potential osteogenic activity present in the water-soluble matrix proteins from Crassostrea gigas nacre using a proteomic approach. Sci. World J. 2012, 2012, 765909. [CrossRef]
7. Kim, S.K.; Pallela, R. Medicinal foods from marine animals: Current status and prospects. Adv. Food Nutr. Res. 2012, 65, 1–9. [PubMed]
8. Lin, S.; Hao, G.; Lai, D.; Tian, Y.; Long, M.; Lai, F.; Xiong, Y.; Ji, C.; Zang, Y. Effect of oyster meat preload on postmeal glycemic control in healthy young adults. J. Am. Coll. Nutr. 2019, 1–7. [CrossRef] [PubMed]
9. Visessanguan, W.; Benjakul, S.; Riebroy, S.; Thepkasikul, P. Changes in composition and functional properties of proteins and their contributions to Nham characteristics. Food Chem. 2004, 66, 579–588. [CrossRef]
10. Je, J.-Y.; Park, P.-J.; Jung, W.-K.; Kim, S.-K. Amino acid changes in fermented oyster (Crassostrea gigas) sauce with different fermentation periods. Food Chem. 2005, 91, 15–18. [CrossRef]
11. Je, J.-Y.; Park, J.-Y.; Jung, W.-K.; Park, P.-J.; Kim, S.-K. Isolation of angiotensin I converting enzyme (ACE) inhibitor from fermented oyster sauce. Crassostrea gigas. Food Chem. 2005, 90, 809–814. [CrossRef]
12. Lee, H.; Hwang-Bo, H.; Je, S.; Lee, H.S.; Lim, S.; Kang, C.H.; Kim, G.Y. Fermented oyster extract on growth promotion in Sprague-Dawley rats. Integr. Med. Res. 2020, 9, 100412. [CrossRef] [PubMed]
13. Ihn, H.J.; Kim, J.A.; Lim, S.; Nam, S.H.; Hwang, S.H.; Lim, J.; Kim, G.Y.; Cheu, Y.H.; Jeon, Y.J.; Lee, B.J.; et al. Fermented oyster extract prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis. Nutrients 2019, 11, 1392. [CrossRef] [PubMed]
14. Molagoda, I.M.N.; Karunarathne, W.A.H.M.; Choi, Y.H.; Park, E.K.; Jeon, Y.J.; Lee, B.J.; Kang, C.H.; Kim, G.Y. Fermented oyster extract promotes osteoblast differentiation by activating the Wnt/β-Catenin signaling pathway, leading to bone formation. Biomolecules 2019, 9, 711. [CrossRef]
15. Jeong, J.W.; Choi, S.H.; Han, M.H.; Kim, G.Y.; Park, C.; Hong, S.H.; Lee, B.J.; Park, E.K.; Kim, S.O.; Leem, S.-H.; et al. Protective effects of fermented oyster extract against RANKL-induced osteoclastogenesis through scavenging ROS generation in RAW 264.7 cells. Int. J. Mol. Sci. 2019, 20, 1439. [CrossRef]
16. Wang, Z.; Bian, L.; Mo, C.; Shen, H.; Zhao, L.J.; Su, K.J.; Kukula, M.; Lee, J.T.; Armstrong, D.W.; Recker, R.; et al. Quantification of aminobutyric acids and their clinical applications as biomarkers for osteoporosis. Commun. Biol. 2020, 3, 39. [CrossRef]
17. Bown, A.W.; Shelp, B.J. The metabolism and functions of c-aminobutyric acid. Plant. Physiology. 1997, 115, 1–5. [CrossRef]
18. Ueno, H. Enzymatic and structural aspects on glutamate decarboxylase. J. Mol. Catal. B Enzym. 2000, 10, 67–79. [CrossRef]
36. Spagnoli, A.; Rosenfeld, R.G. The mechanisms by which growth hormone brings about growth. The relative

27. Muhammad, S.I.; Maznah, I.; Mahmud, R.; Zuki, A.B.; Imam, M.U. Upregulation of genes related to

24. Sokovic Bajic, S.; Djokic, J.; Dinic, M.; Veljovic, K.; Golic, N.; Mihajlovic, S.; Tolinacki, M. GABA-producing

19. Lu, X.; Xie, C.; Gu, Z. Isolation of γ-aminobutyric acid-producing bacteria and optimization of fermentative

22. Aoki, H.; Furuya, Y.; Endo, Y.; Fujimoto, K. Effect of gamma-aminobutyric acid-enriched tempeh-like

25. Shang, W.; Si, X.; Zhou, Z.; Strappe, P.; Blanchard, C. Wheat bran with enriched gamma-aminobutyric

20. Jeng, K.C.; Chen, C.S.; Fang, Y.P.; Hou, R.C.W.; Chen, Y.S. Isolation of

21. Dhakal, R.; Baipai, V.K.; Baek, K.H. Production of gaba (γ-Aminobutyric acid) by microorganisms: A review. 

23. Park, N.H.; Lee, S.J.; Mechesso, A.F.; Boby, N.; Yixian, Q.; Yoon, W.K.; Lee, S.P.; Lee, J.S.; Park, S.C. 

Hepatoprotective effects of gamma-aminobutyric acid-enriched fermented Hovenia dulcis extract on ethanol-induced liver injury in mice. BMC Complement. Med. Ther. 2020, 20, 75. [CrossRef] [PubMed]

26. Watanabe, M.; Maemura, K.; Kanbara, K.; Tamayama, T.; Hayasaki, H. GABA and GABA receptors in the 

central nervous system and other organs. Int. Rev. Cytol. 2002, 213, 1–47.

27. Muhammad, S.I.; Maznah, I.; Mahmud, R.; Zuki, A.B.; Imam, M.U. Upregulation of genes related to 

bone formation by γ-amino butyric acid and γ-oryzanol in germinated brown rice is via the activation of 

GABAB-receptors and reduction of serum IL-6 in rats. Clin. Interv. Aging 2013, 8, 1259–1271. [CrossRef]

28. Racagni, G.; Apud, J.A.; Cocchi, D.; Locatelli, V.; Muller, E.E. GABAergic control of anterior pituitary hormone 

secretion. Life Sci. 1982, 31, 823–838. [CrossRef]

29. Nilsson, O.; Marino, R.; De Luca, F.; Phillip, M.; Baron, J. Endocrine regulation of the growth plate. Horm. 

Res. Paediatr. 2005, 64, 157–165. [CrossRef]

30. Esposito, S.; Leonardi, A.; Lanciotti, L.; Cofini, M.; Muzi, G.; Penta, L. Vitamin D and growth hormone in 

children: A review of the current scientific knowledge. J. Transl. Med. 2019, 17, 87. [CrossRef]

31. Betts, P. Which children should receive growth hormone treatment. Long term side effects possible with 

high doses. Arch. Dis. Child. 2000, 83, 176–178. [PubMed]

32. Svensson, J.; Lall, S.; Dickson, S.I.; Bengtsson, B.A.; Rømer, J.; Ahnfelt-Rønne, I.; Ohlsson, C.; Jansson, J.O. 

Effects of growth hormone and its secretagogues on bone. Endocrine 2001, 14, 63–66. [CrossRef]

33. Olney, R.C. Regulation of bone mass by growth hormone. Med. Pediatr. Oncol. 2003, 41, 228–234. [CrossRef] 

[PubMed]

34. Baron, J.; Sävendahl, L.; De Luca, F.; Dauber, A.; Phillip, M.; Wit, J.M.; Nilsson, O. Short and tall stature: A 

new paradigm emerges. Nat. Rev. Endocrinol. 2015, 11, 735–746. [CrossRef] [PubMed]

35. Binoux, M.; Hossenlopp, P. Insulin-like growth factor (IGF) and IGF-binding proteins: Comparison of human 

serum and lymph. J. Clin. Endocrinol. Metab. 1988, 67, 509–514. [CrossRef]

36. Spagnoli, A.; Rosenfeld, R.G. The mechanisms by which growth hormone brings about growth. The relative 

contributions of growth hormone and insulin-like growth factors. Endocrinol. Metab. Clin. North. Am. 1996, 

25, 615–631. [CrossRef]

37. Baker, J.; Liu, J.P.; Robertson, E.J.; Efstratiadis, A. Role of insulinlike growth factors in embryonic and 

postnatal growth. Cell 1993, 75, 73–82. [CrossRef]

38. Roith, D.L.; Bondy, C.; Yakar, S.; Liu, J.L.; Butler, A. The somatomedin hypothesis: 2001. Endocr. Rev. 2001, 

22, 53–74. [CrossRef]

39. Firth, S.M.; Baxter, R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 2002, 

23, 824–854. [CrossRef]

40. Barrios, V.; Argente, J.; Munoz, M.T.; Pozo, J.; Chowen, J.A.; Hernandez, M. Diagnostic interest of acid-labile 

subunit measurement in relationship to other components of the igf system in pediatric patients with growth 

or eating disorders. Eur. J. Endocrinol. 2001, 144, 245–250. [CrossRef]

41. Rosenfeld, R.G. Is growth hormone deficiency a viable diagnosis? J. Clin. Endocrinol. Metab. 1997, 82, 

349–351. [CrossRef] [PubMed]
42. Van der Kaay, D.C.; Hendriks, A.E.; Ester, W.A.; Leunissen, R.W.; Willemsen, R.H.; de Kort, S.W.; Paquette, J.R.; Hokken-Koelega, A.C.; Deal, C.L. Genetic and epigenetic variability in the gene for IGFBP-3 (IGFBP3): Correlation with serum IGFBP-3 levels and growth in short children born small for gestational age. *Growth Horm. IGF Res*. 2009, **19**, 198–205. [CrossRef] [PubMed]

43. Lee, D.; Kim, Y.S.; Song, J.; Kim, H.S.; Lee, H.J.; Guo, H.; Kim, H. Effects of *Phlomis umbrosa* root on longitudinal bone growth rate in adolescent female rats. *Molecules* 2016, **21**, 461. [CrossRef] [PubMed]

44. Kim, M.Y.; Kim, J.Y.; Lim, D.; Lee, D.; Kim, Y.; Chang, G.T.; Choi, H.Y.; Kim, H. Skeletal growth and IGF levels in rats after HT042 treatment. *Phytother. Res.* 2012, **26**, 1771–1778. [CrossRef]

45. Nishiyama, K.; Sugimoto, T.; Kaji, H.; Kanatani, M.; Kobayashi, T.; Chihara, K. Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation. *Endocrinology* 1996, **137**, 35–41. [CrossRef]

46. Weise, M.; De-Levi, S.; Barnes, K.M.; Gafni, R.I.; Abad, V.; Baron, J. Effects of estrogen on growth plate senescence and epiphyseal fusion. *Proc. Natl. Acad. Sci. USA* 2001, **98**, 6871–6876. [CrossRef]

47. Schenk, R.K.; Hunziker, E.B. *Rickets*; Glorieux, F.H., Ed.; Nestle Nutrition Workshop Series; Raven: New York, NY, USA, 1991; pp. 63–76.

48. Ballock, R.T.; O’Keefe, R.J. The biology of the growth plate. *J. Bone Joint Surg. Am.* 2003, **85**, 715–726. [CrossRef]

49. Abad, V.; Meyers, J.L.; Weise, M.; Gafni, R.I.; Barnes, K.M.; Nilsson, O.; Bacher, J.D.; Baron, J. The role of the resting zone in growth plate chondrogenesis. *Endocrinology* 2002, **143**, 1851–1857. [CrossRef]

50. Stokes, I.A.; Clark, K.C.; Farnum, C.E.; Aronsson, D.D. Alterations in the growth plate associated with growth modulation by sustained compression or distraction. *Bone* 2007, **41**, 197–205. [CrossRef]

51. Hallett, S.A.; Ono, W.; Ono, N. Growth plate chondrocytes: Skeletal development, growth and beyond. *Int. J. Mol. Sci.* 2019, **20**, 6009. [CrossRef]

52. Storm, E.E.; Huynh, T.V.; Copeland, N.G.; Jenkins, N.A.; Kingsley, D.M.; Lee, S.J. Limb alterations in genetically engineered flavonol enriched tomato fruit modulates chondrogenesis to increase bone length in growing animals. *Molecules* 2019, **25**, 4375. [CrossRef] [PubMed]

53. Shu, B.; Zhang, M.; Xie, R.; Wang, M.; Jin, H.; Hou, W.; Tang, D.; Harris, S.E.; Mishina, Y.; O’Keefe, R.J.; et al. BMP2 activity and not BMP4, is crucial for chondrocyte proliferation and maturation during endochondral bone development. *J. Cell Sci.* 2011, **124**, 3428–3440. [CrossRef] [PubMed]

54. Tsuji, K.; Bandyopadhayay, A.; Harfe, B.D.; Cox, K.; Kakar, S.; Gerstenfeld, L.; Einhorn, T.; Tabin, C.J.; Rosen, V. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. *Nat. Genet.* 2006, **38**, 1424–1429. [CrossRef] [PubMed]

55. Wu, M.; Chen, G.; Li, Y.P. TGF- and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. *Bone* 2016, **4**, 16009. [CrossRef]

56. Lee, B.J.; Kim, J.S.; Kang, Y.M.; Lim, J.H.; Kim, Y.M.; Lee, M.S.; Ahn, C.B.; Je, J.Y. Antioxidant activity and γ-aminobutyric acid (GABA) content in sea tangle fermented by *Lactobacillus brevis* B[20] isolated from traditional fermented foods. *Food Chem.* 2010, **122**, 271–276. [CrossRef]

57. Seo, M.S.; Kim, Y.I.; Kang, K.K.; Oh, S.K.; Sung, S.E.; Jung, Y.S.; Cho, J.Y.; Song, H.; Hwang, D.Y.; Park, S.J.; et al. Comparison study of the response with botulinum toxin muscle injection in the ICR mice from three different sources. *Lab. Anim. Res.* 2019, **35**, 11. [CrossRef]

58. Xian, C.J.; Cool, J.C.; van Gangel, J.; Foster, B.K.; Howarth, G.S. Effect of etoposide and cyclophosphamide acute chemotherapy on growth plate and metaphyseal bone in rats. *Cancer Biol. Ther.* 2007, **6**, 170–177. [CrossRef]

59. Choudhary, D.; Pandey, A.; Adhikary, S.; Ahmad, N.; Bhatia, C.; Bhamkhani, S.; Trivedi, P.K.; Trivedi, R. Genetically engineered flavonol enriched tomato fruit modulates chondrogenesis to increase bone length in growing animals. *Sci. Rep.* 2016, **6**, 21668. [CrossRef]

60. Jensen, E.C. Quantitative analysis of histological staining and fluorescence using ImageJ. *Anat. Rec.* 2013, **296**, 378–381. [CrossRef] [PubMed]